Tag : Psychedelics

CCT Impact

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

CCT IMPACT Agent
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced it has executed a license agreement with Monash University (‘Monash University’ or ‘Monash’) to develop a novel treatment that combines Virtual......
CCT Impact

Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address Anxiety, Depression and PTSD

CCT IMPACT Agent
A new survey conducted by The Harris Poll on behalf of Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, reports that nearly two thirds of Americans who suffer from anxiety/depression/PTSD (65%) believe that psychedelic medicine (i.e. ketamine,......
CCT Impact

Delic Labs Applies for Dealer’s License to Commercialize Psychedelics Research, Health Exemption to Test MDMA and LSD

CCT IMPACT Agent
Delic Holding Corp Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), the leading psychedelic wellness platform, today announced Delic Labs has applied for a Health Canada 56 Research Exemption that would allow the scientists to perform research and tests on a host of compounds outside of psychedelic mushrooms, including......
CCT Impact

NAVIGESIA: Personalized Medicine Data Platform for Clinical Neurosciences and Emerging Therapeutics (Cannabis, Psychedelics, Nootropics)

CCT IMPACT Agent
NAVIGESIA, a personalized medicine software company expands their real-world data tools for clinical neurology and psychology industries, supporting patient management with psychoactive compounds: cannabis, psychedelics, nootropics. The NAVIGESIA platform helps teams collect quantifiable information for the purposes of building the best real-world representations for clinical stories and journeys. From baseline assessments to......
CCT Impact

MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index

CCT IMPACT Agent
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) is pleased to announce its inclusion among 17 psychedelic companies in the first ever Psychedelic ETF. Horizon’s Psychedelic ETF, is expected to commence trading Jan. 26, 2021 under ticker PSYK on the NEO exchange. The ETF includes companies in the Canadian......
CCT Impact

KCSA Strategic Communications Announces Agenda for the KCSA Psychedelics Investor Conference on January 26-27, 2021

CCT IMPACT Agent
KCSA Strategic Communications, an integrated strategic communications firm specializing in public relations, investor relations and social media, today announced the agenda for its inaugural virtual Psychedelics Investor Conference to be held on Tuesday, January 26, 2021 and Wednesday, January 27, 2021 from 9:00am – 12:30pm ET. Tuesday, January 26, 2021 Time Topic Speaker 9:00am Opening Remarks KCSA......